RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vistin Pharma A Stock

Vistin Pharma A ROE 2024

Vistin Pharma A ROE

0

Ticker

VISTN.OL

ISIN

NO0010734122

WKN

A14TLR

In 2024, Vistin Pharma A's return on equity (ROE) was 0, a -100% increase from the -0.02 ROE in the previous year.

Vistin Pharma A Aktienanalyse

What does Vistin Pharma A do?

Vistin Pharma ASA is a Norwegian company specializing in the production and sale of chemical products. The company was founded in 1997 and is headquartered in Oslo. History: The company started as a chemical products manufacturer but quickly began focusing on the production of pharmaceutical products and active ingredients in the early 2000s. In 2016, the subsidiary Vistin Pharma Production AS was established, specializing in the production of active ingredients for the chemical industry. Business model: Vistin Pharma is a niche provider of specialized chemical and pharmaceutical products. The company focuses on producing high-quality products for selected markets and industries where it has a competitive position. The business model is based on a combination of advanced research and development, state-of-the-art production facilities, and a comprehensive network of sales partners and distributors. Different divisions: Vistin Pharma's business activities mainly focus on two main divisions: Pharmaceuticals and Industrial Active Ingredients. The Pharmaceuticals division includes the production and sale of active ingredients for the production of human and animal health medications. The products include Metformin, an active ingredient for treating diabetes, as well as Methotrexate tablets for cancer treatment. The Industrial Active Ingredients division produces active ingredients for various industries, including cosmetics, food, and energy sectors. Products: One of Vistin Pharma's best-known products is Metformin, an orally administered medication for treating type 2 diabetes. Metformin helps control and lower blood sugar levels by preventing the liver from producing too much glucose and improving the body's sensitivity to insulin. Vistin Pharma's Methotrexate tablets are used to treat a variety of cancers, including breast cancer, lung cancer, and leukemia. Overall, Vistin Pharma offers a wide range of chemical and pharmaceutical products suitable for various applications. The company places great emphasis on quality and sustainability and strives to offer its customers high-quality and environmentally friendly products and services. Conclusion: Vistin Pharma is an innovative Norwegian pharmaceutical and chemical company that has been focused on producing and selling high-quality products since its inception. With a wide range of chemical and pharmaceutical products and a strong focus on research and development, product quality, and sustainability, Vistin Pharma is well-positioned to continue growing and establish itself as a leading provider in its core markets. The output translation is: Vistin Pharma ASA is a Norwegian company specializing in the production and sale of chemical and pharmaceutical products. It was founded in 1997 and is headquartered in Oslo. The company has expanded from being a chemical products manufacturer to producing pharmaceutical products and active ingredients. It operates through two main divisions: Pharmaceuticals and Industrial Active Ingredients. Vistin Pharma's products include Metformin for treating diabetes and Methotrexate tablets for cancer treatment. The company focuses on providing high-quality and environmentally friendly products and services. With its strong emphasis on research and development, product quality, and sustainability, Vistin Pharma aims to become a leading player in its core markets. Vistin Pharma A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Vistin Pharma A's Return on Equity (ROE)

Vistin Pharma A's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Vistin Pharma A's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Vistin Pharma A's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Vistin Pharma A’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Vistin Pharma A stock

What is the ROE (Return on Equity) of Vistin Pharma A this year?

The ROE of Vistin Pharma A this year is 0 undefined.

How has the Return on Equity (ROE) of Vistin Pharma A developed compared to the previous year?

The ROE of Vistin Pharma A has increased by -100% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Vistin Pharma A?

A high ROE indicates that Vistin Pharma A generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Vistin Pharma A?

A low ROE can indicate that Vistin Pharma A is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Vistin Pharma A affect the company?

A change in ROE (Return on Equity) of Vistin Pharma A can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Vistin Pharma A?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Vistin Pharma A?

Some factors that can influence Vistin Pharma A's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Vistin Pharma A pay?

Over the past 12 months, Vistin Pharma A paid a dividend of 0.75 NOK . This corresponds to a dividend yield of about 2.87 %. For the coming 12 months, Vistin Pharma A is expected to pay a dividend of 0.75 NOK.

What is the dividend yield of Vistin Pharma A?

The current dividend yield of Vistin Pharma A is 2.87 %.

When does Vistin Pharma A pay dividends?

Vistin Pharma A pays a quarterly dividend. This is distributed in the months of June, February, July, December.

How secure is the dividend of Vistin Pharma A?

Vistin Pharma A paid dividends every year for the past 0 years.

What is the dividend of Vistin Pharma A?

For the upcoming 12 months, dividends amounting to 0.75 NOK are expected. This corresponds to a dividend yield of 2.87 %.

In which sector is Vistin Pharma A located?

Vistin Pharma A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vistin Pharma A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vistin Pharma A from 11/19/2024 amounting to 0.5 NOK, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Vistin Pharma A pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Vistin Pharma A in the year 2023?

In the year 2023, Vistin Pharma A distributed 0.5 NOK as dividends.

In which currency does Vistin Pharma A pay out the dividend?

The dividends of Vistin Pharma A are distributed in NOK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vistin Pharma A

Our stock analysis for Vistin Pharma A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vistin Pharma A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.